{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:35:05Z","timestamp":1791275705884,"version":"4.1.0"},"reference-count":35,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2002,1,6]],"date-time":"2002-01-06T00:00:00Z","timestamp":1010275200000},"content-version":"vor","delay-in-days":31,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Pharma Physio"],"published-print":{"date-parts":[[2001,12,6]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>1. Familial hyperkalaemic hypertension (FHH), also called pseudohypoaldosteronism type II (PHA2) or Gordon syndrome, is a rare Mendelian\u2010form of low\u2010renin hypertension. The first cases of FHH were reported approximately 30 years ago and they described the peculiar biochemical abnormalities (i.e. hyperkalaemia and hyperchloraemic acidosis despite a normal glomerular filtration rate).<\/jats:p><jats:p>2. Since then, more than 90 single cases and families have been reported in the literature. These various reports show marked differences in phenotype.<\/jats:p><jats:p>3. Our group has now collected 14 unrelated pedigrees originating from different parts of France and Europe. We confirm the large variations in the age of discovery and in the severity of the biochemical abnormalities from one individual to another and from one family to another one.<\/jats:p><jats:p>4. Blood pressure levels have no significant relationship with hyperkalaemia or hyperchloraemia, but there is a positive relationship with age, as in the normal population.<\/jats:p><jats:p>5. Analyses of clinical features and Mendelian segregation in our families demonstrate autosomal\u2010dominant inheritance, as expected from the literature.<\/jats:p><jats:p>6. Efforts have been made in the past years to unravel the gene responsible for the disease. Until now, a primary responsability of the gene encoding the thiazide\u2010sensitive Na\u2013Cl cotransporter (SLC12A3) has been excluded in PHA2 families. Three loci have been identified on chromosomes 1 (PHA2A), 17 (PHA2B) and 12 (PHA2C).<\/jats:p><jats:p>7. More recently, analysis of three additional pedigrees, including 10 affected subjects, with over 25 members allowed us to demonstrate further genetic heterogeneity and the existence of at least a fourth locus.<\/jats:p><jats:p>8. The genetic heterogeneity of this syndrome, and thus the variety of molecular defects, suggests the role of either several new components of the same pathway, multiple aldosterone\u2010 regulated effectors or direct or indirect partners of the Na\u2013Cl cotransporter.<\/jats:p>","DOI":"10.1046\/j.1440-1681.2001.03575.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T11:08:22Z","timestamp":1047380902000},"page":"1048-1052","source":"Crossref","is-referenced-by-count":75,"title":["Phenotypic And Genetic Heterogeneity Of Familial Hyperkalaemic Hypertension (Gordon Syndrome)"],"prefix":"10.1111","volume":"28","author":[{"given":"Jean\u2010Michel","family":"Achard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Disse\u2010Nicodeme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Fiquet\u2010Kempf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Jeunemaitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,1,6]]},"reference":[{"key":"e_1_2_6_2_2","unstructured":"GordonRD KlemmSA TunnyTJ StowasserM.Gordon\u2019s syndrome: A sodium\u2010volume\u2010dependent form of hypertension with a genetic basis. In: Laragh JH Brenner BM (eds).Hypertension: Pathophysiology Diagnosis and Management.Raven Press New York. 1995; 2111\u201323."},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(69)90230-7"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.138.4.607"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.138.12.1837"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1981.72"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/imj.1970.19.4.287"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng0196-24"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1964.tb115766.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1968.tb83401.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-198812040-00100"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.1990.tb01304.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.6.3.266"},{"key":"e_1_2_6_14_2","doi-asserted-by":"crossref","unstructured":"BeckerK&SplittM.A family with distal arthrogryposis and cleft palate: Possible overlap between Gordon syndrome and Aase\u2013Smith syndrome.Clin. Dysmorphol.2001;10: 41\u20135.","DOI":"10.1097\/00019605-200101000-00009"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(96)70131-2"},{"key":"e_1_2_6_16_2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1542\/peds.69.3.317","article-title":"Severe hypertension, hyperkalemia, and renal tubular acidosis responding to dietary sodium restriction.","volume":"69","author":"Sanjad SA","year":"1982","journal-title":"Pediatrics"},{"key":"e_1_2_6_17_2","first-page":"245","article-title":"Hypertension and hyperkalaemia responding to bendrofluazide.","volume":"48","author":"Lee MR","year":"1979","journal-title":"Q. J. Med."},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410260314"},{"key":"e_1_2_6_19_2","unstructured":"ThrockmortonDC&BiaMJ.Pseudohypoaldosteronism: Case report and discussion of the syndrome.Yale J. Biol. Med.1991;64: 247\u201354."},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03348032"},{"key":"e_1_2_6_21_2","doi-asserted-by":"crossref","unstructured":"SemmekrotB&MonnensLA.Furosemide versus thiazide in Gordon syndrome.Eur. J. Pediatr.1996;155: 621.","DOI":"10.1007\/BF01957921"},{"key":"e_1_2_6_22_2","unstructured":"Disse\u2010NicodemeS AchardJM PotierJet al.Hypertension hyperkali\u00e9mique familiale (syndrome de Gordon): Analyse de la variabilit\u00e9 ph\u00e9notypique par l\u2019\u00e9tude de 7 familles. In: Gr\u00fcnfeld J\u2010P Bach J\u2010F Kreis H (eds).Act N\u00e9phrol.Flammarion M\u00e9decine\u2010Sciences Paris. 2001; 59\u201371."},{"key":"e_1_2_6_23_2","doi-asserted-by":"crossref","unstructured":"Disse\u2010NicodemeS AchardJM DesitterIet al.A new locus on chromosome 12p13.3 for pseudohypoaldosteronism type II an autosomal dominant form of hypertension.Am. J. Hum. Genet.2000;67: 302\u201310.","DOI":"10.1086\/303020"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng0697-202"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/353521a0"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(91)90584-L"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1000705"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/6.12.2077"},{"key":"e_1_2_6_29_2","doi-asserted-by":"crossref","unstructured":"LevyD DeStefanoAL LarsonMGet al.Evidence for a gene influencing blood pressure on chromosome 17. Genome scan linkage results for longitudinal blood pressure phenotypes in subjects from the framingham heart study.Hypertension2000;36: 477\u201383.","DOI":"10.1161\/01.HYP.36.4.477"},{"key":"e_1_2_6_30_2","doi-asserted-by":"crossref","unstructured":"Disse\u2010NicodemeS DesitterI Fiquet\u2010KempfBet al.Genetic heterogeneity of familial hyperkalaemic hypertension.J. Hypertens.2001 (in press).","DOI":"10.1097\/00004872-200111000-00005"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1973.38"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.1986.tb00358.x"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(74)80115-0"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo-117-5-1772"},{"key":"e_1_2_6_35_2","first-page":"922","article-title":"Suppression of plasma renin activity in a boy with chronic hyperkalemia.","volume":"141","author":"Sauder SE","year":"1987","journal-title":"Am. J. Dis. Child."},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1159\/000167172"}],"container-title":["Clinical and Experimental Pharmacology and Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1440-1681.2001.03575.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1440-1681.2001.03575.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T23:25:15Z","timestamp":1697412315000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1440-1681.2001.03575.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,12,6]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2001,12,6]]}},"alternative-id":["10.1046\/j.1440-1681.2001.03575.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1440-1681.2001.03575.x","archive":["Portico"],"relation":{},"ISSN":["0305-1870","1440-1681"],"issn-type":[{"value":"0305-1870","type":"print"},{"value":"1440-1681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,12,6]]}}}